share_log

Zentek Launches National Sampling Program for ZenGUARD Antimicrobial Surgical Masks

Zentek Launches National Sampling Program for ZenGUARD Antimicrobial Surgical Masks

Zentek推出ZenGUARD抗菌外科口罩全國採樣計劃
Zentek ·  07/24 00:00

Guelph, ON – July 24, 2024, Zentek Ltd. ("Zentek" or the "Company") (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company announces that it will embark on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. ("Henry Schein") that will see ZenGUARD Antimicrobial Surgical Masks included in product shipments to Henry Schein customers.

安大略省蓋爾夫——2024年7月24日,知識產權開發和商業化公司Zentek Ltd.(“Zentek” 或 “公司”)(納斯達克股票代碼:ZEN)宣佈,它將啓動一項由亨利·謝因公司(“Henry Schein”)推動的加拿大範圍內的牙科專業人員抽樣計劃,該計劃將把ZenGuard抗菌外科口罩納入向亨利·舍因的產品運送中顧客。

In addition to offering dental practitioners and their patients a surgical mask with better protection against infectious agents, ZenGUARD Antimicrobial Surgical Masks are also proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. The Company believes this program will introduce ZenGUARD Antimicrobial Surgical Masks and this unique value proposition to nearly all Henry Schein customers across Canada.

ZenGuard 抗菌外科口罩除了爲牙科醫生及其患者提供可更好地抵禦傳染病原體的外科口罩外,還被證明可以消除 99.9% 的細菌,這些細菌會在長時間佩戴外科口罩時積聚在皮膚上並導致粉刺。該公司認爲,該計劃將向加拿大幾乎所有Henry Schein客戶介紹ZenGuard抗菌外科口罩和這一獨特的價值主張。

"The safety of staff and patients in dental practices is paramount, and surgical masks play a crucial role as they serve as a primary barrier against the transmission of infectious agents, including bacteria, viruses, and other pathogens. With the ability for ZenGUARD Antimicrobial Surgical Masks to eliminate bacteria and filter more virus particles compared to standard ASTM Level 3 surgical masks, we believe that this technology should be the new standard of protection for this incredibly important market segment," said Greg Fenton, Zentek CEO.

“牙科診所工作人員和患者的安全至關重要,外科口罩起着至關重要的作用,因爲它們是抵禦傳染原體(包括細菌、病毒和其他病原體)傳播的主要屏障。與標準的AstM Level 3外科口罩相比,ZenGuard抗菌外科口罩能夠消除細菌並過濾更多的病毒顆粒,因此我們認爲這項技術應該成爲這個極其重要的細分市場的新保護標準。” Zentek首席執行官格雷格·芬頓說。

About Zentek Ltd.

關於 Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek是一家通過ISO 13485:2016 認證的知識產權技術公司,專注於新產品的研究、開發和商業化,旨在通過使公司的商業合作伙伴的產品更好、更安全、更環保,從而爲其商業合作伙伴提供競爭優勢。

Zentek's patented technology platform ZenGUARD, is shown to have 99-per-cent anti-microbial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD production facility is in Guelph, Ontario.

Zentek的專利技術平台ZenGuard被證明具有99%的抗微生物活性,可顯著提高外科口罩的病毒過濾效率,其目標是對HVAC(供暖、通風和空調)系統起到同樣的作用。Zentek的ZenGuard生產設施位於安大略省圭爾夫。

For further information on Zentek:

有關 Zentek 的更多信息:

investorrelations@zentek.com

investorrelations@zentek.com

Ryan Shacklock

Ryan Shacklock

Senior VP, Strategy & Business Development

戰略與業務發展高級副總裁

Email: rshacklock@zentek.com

電子郵件:rshacklock@zentek.com

Phone: 306-270-9610

電話:306-270-9610

To find out more about Zentek, please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at .

要了解有關 Zentek 的更多信息,請訪問我們的網站。本新聞稿和與公司有關的所有重要文件的副本可在Zentek的SEDAR+個人資料上獲得,網址爲。

Forward-Looking Statements

前瞻性陳述

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

本新聞稿包含前瞻性陳述。由於前瞻性陳述涉及未來的事件和狀況,因此就其本質而言,它們涉及固有的風險和不確定性。儘管Zentek認爲在本新聞稿中準備前瞻性信息時使用的假設和因素是合理的,但不應過度依賴此類信息,這些信息僅適用於本新聞稿發佈之日,也無法保證此類事件會在披露的時間範圍內或根本不會發生。除法律要求外,Zentek不打算或有義務更新或修改任何前瞻性信息,無論是由於新信息、未來事件還是其他原因。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論